These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 28967706)

  • 1. Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects.
    Kropeit D; von Richter O; Stobernack HP; Rübsamen-Schaeff H; Zimmermann H
    Clin Pharmacol Drug Dev; 2018 Jan; 7(1):9-21. PubMed ID: 28967706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic Drug-Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil.
    McCrea JB; Macha S; Adedoyin A; Marshall W; Menzel K; Cho CR; Liu F; Zhao T; Levine V; Kraft WK; Yoon E; Panebianco D; Stoch SA; Iwamoto M
    J Clin Pharmacol; 2019 Oct; 59(10):1331-1339. PubMed ID: 30990905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy Subjects.
    Marshall WL; McCrea JB; Macha S; Menzel K; Liu F; van Schanke A; de Haes JIU; Hussaini A; Jordan HR; Drexel M; Kantesaria BS; Tsai C; Cho CR; Hulskotte EGJ; Butterton JR; Iwamoto M
    J Clin Pharmacol; 2018 Jul; 58(7):897-904. PubMed ID: 29578577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment.
    Kropeit D; McCormick D; Erb-Zohar K; Moiseev VS; Kobalava ZD; Stobernack HP; Zimmermann H; Rübsamen-Schaeff H
    Br J Clin Pharmacol; 2017 Dec; 83(12):2678-2686. PubMed ID: 28722153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic Interaction between Faldaprevir and Cyclosporine or Tacrolimus in Healthy Volunteers: A Prospective, Open-Label, Fixed-Sequence, Crossover Study.
    Huang F; Voelk C; Trampisch M; Rowland L; Schultz A; Sabo JP
    Basic Clin Pharmacol Toxicol; 2018 Jul; 123(1):84-93. PubMed ID: 29427400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment.
    Kropeit D; Scheuenpflug J; Erb-Zohar K; Halabi A; Stobernack HP; Hulskotte EGJ; van Schanke A; Zimmermann H; Rübsamen-Schaeff H
    Br J Clin Pharmacol; 2017 Sep; 83(9):1944-1953. PubMed ID: 28345163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers.
    Hulskotte E; Gupta S; Xuan F; van Zutven M; O'Mara E; Feng HP; Wagner J; Butterton J
    Hepatology; 2012 Nov; 56(5):1622-30. PubMed ID: 22576324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers.
    Zaltzman JS
    Transplantation; 2010 Dec; 90(11):1185-91. PubMed ID: 21166111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation.
    Turolo S; Tirelli AS; Ferraresso M; Ghio L; Belingheri M; Groppali E; Torresani E; Edefonti A
    Pharmacol Rep; 2010; 62(6):1159-69. PubMed ID: 21273673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus.
    Garg V; van Heeswijk R; Lee JE; Alves K; Nadkarni P; Luo X
    Hepatology; 2011 Jul; 54(1):20-7. PubMed ID: 21618566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Pharmacokinetic Interaction Between Letermovir and Fluconazole in Healthy Participants.
    Adedoyin A; Fancourt C; Menzel K; Zhao T; Tomek C; Panebianco D; McCrea JB; Stoch SA; Iwamoto M
    Clin Pharmacol Drug Dev; 2021 Feb; 10(2):198-206. PubMed ID: 32700459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients.
    Falck P; Vethe NT; Asberg A; Midtvedt K; Bergan S; Reubsaet JL; Holdaas H
    Nephrol Dial Transplant; 2008 Mar; 23(3):1048-53. PubMed ID: 17956893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Oral Letermovir Administration on the Pharmacokinetics of a Single Oral Dose of P-Glycoprotein Substrate Digoxin in Healthy Volunteers.
    Scheuenpflug J; Kropeit D; Erb-Zohar K; Theis JGW; Stobernack HP; McCormick D; Zimmermann H; Rübsamen-Schaeff H
    Clin Pharmacol Drug Dev; 2022 Jan; 11(1):6-15. PubMed ID: 34812580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy Volunteers.
    Feng HP; Caro L; Fandozzi CM; Guo Z; Talaty J; Wolford D; Panebianco D; Iwamoto M; Butterton JR; Yeh WW
    J Clin Pharmacol; 2018 May; 58(5):666-673. PubMed ID: 29329497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients.
    Lam H; Jeffery J; Sitar DS; Aoki FY
    Ther Drug Monit; 2011 Dec; 33(6):699-704. PubMed ID: 22105586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus.
    Sansone-Parsons A; Krishna G; Martinho M; Kantesaria B; Gelone S; Mant TG
    Pharmacotherapy; 2007 Jun; 27(6):825-34. PubMed ID: 17542765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrolimus Concentration after Letermovir Initiation in Hematopoietic Stem Cell Transplantation Recipients Receiving Voriconazole: A Retrospective, Observational Study.
    Hikasa S; Shimabukuro S; Osugi Y; Ikegame K; Kaida K; Fukunaga K; Higami T; Tada M; Tanaka K; Yanai M; Kimura T
    Int J Med Sci; 2020; 17(7):859-864. PubMed ID: 32308538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letermovir for prophylaxis of cytomegalovirus in allogeneic hematopoietic stem cell recipients.
    Cho JC; Le AD; Locke SC
    Drugs Today (Barc); 2018 Jun; 54(6):361-368. PubMed ID: 29998227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients.
    Elens L; van Schaik RH; Panin N; de Meyer M; Wallemacq P; Lison D; Mourad M; Haufroid V
    Pharmacogenomics; 2011 Oct; 12(10):1383-96. PubMed ID: 21902502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, Safety, and Tolerability of Letermovir Following Single- and Multiple-Dose Administration in Healthy Japanese Subjects.
    Asari K; Ishii M; Yoshitsugu H; Wakana A; Fancourt C; Yoon E; Furihata K; McCrea JB; Stoch SA; Iwamoto M
    Clin Pharmacol Drug Dev; 2022 Aug; 11(8):938-948. PubMed ID: 35238179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.